Discoverer of Magainins, the first of a new class of anti-infectives, to
advise Company on pexiganan development
WELLESLEY HILLS, Mass., Oct. 17 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) today announced that following its acquisition of rights to pexiganan, Michael Zasloff, M.D. has joined the company's Scientific Advisory Board. Dr. Zasloff discovered magainins in the skin of the African clawed frog while at NIH (National Institutes of Health) and later pioneered the development of magainins, and specifically pexiganan, as human anti-infective drugs.
"Along with Tom Chan, Ph.D., Chairman of our Scientific Advisory Board, we welcome Dr. Zasloff," said Robert J. DeLuccia, President and CEO of MacroChem. We are very pleased to have his knowledge and experience helping to guide us in advancing the development of pexiganan."
Michael Zasloff, M.D., Ph.D. is currently Professor of Surgery and
Pediatrics at the Georgetown University School of Medicine. An
internationally known biomedical researcher, Dr. Zasloff was previously
Dean of Research and Translational Science at the Georgetown University
Medical Center, responsible for the overall management of Georgetown's
biomedical research and its translation from the laboratory to patient
care. Dr. Zasloff has been a pioneer in the field of innate immunity. His
studies have helped elucidate the pathophysiology of chronic infections in
diseases such as cystic fibrosis. In addition, he has been the leader in
the discovery of antimicrobial peptides and aminosterols of animal and
human origin and their development as human therapeutics. Dr. Zasloff
earned his M.D., Ph.D. at New York University School of Medicine in the
Medical Scientist Training Program, sponsored by the National Institutes of
Health. He served his Residency in pediatrics at the Boston Children's
Hospital. In 1975 he joined the National Institutes of Health for
postdoctoral studies in mo
|SOURCE MacroChem Corporation|
Copyright©2007 PR Newswire.
All rights reserved